Indications and uses
temporary relief of nasal congestion due to the common cold due to hay fever or other upper respiratory allergies associated with sinusitis reduces swelling of nasal passages temporarily restores freer breathing through the nose
temporary relief of nasal congestion due to the common cold due to hay fever or other upper respiratory allergies associated with sinusitis reduces swelling of nasal passages temporarily restores freer breathing through the nose
Adults and children 6 to under 12 years of age (with supervision): 2 to 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period. Children under 6 years of age: ask a doctor To spray: squeeze the bottle quickly and firmly. Do not tilt head backward while spraying. Wipe nozzle clean after use.
Drug Facts
Oxymetazoline hydrochloride 0.05%
Nasal decongestant
Do not exceed recommended dosage
This product may cause temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge. The use of this container by more than one person may spread infection.
If pregnant or breast-feeding,ask a health professional before use.
Keep out of reach of children.If swallowed, get medical help or contact a Poison Control Center right away.
benzalkonium chloride, dibasic sodium phosphate (anhydrous), edetate disodium (dihydrate), monobasic sodium phosphate (monohydrate), polyethylene glycol 1450, povidone, propylene glycol, purified water.
Call 1-866-923-4914
Distributed by:
Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, NY 10532
Compare to the
active ingredient
in Afrin
®*
Nasal
Decongestant
12- Hour Spray
Oxymetazoline
Hydrochloride 0.05%
Maximum Strength
Contains the Active Ingredient
Recommended Most by
Physicians and Pharmacists
12
1 fl oz (30 mL)

| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| e67be450-f8e4-4bc1-88bd-1259d379f55f | Product name | 1 | 20210127 |
| c53f3286-4062-4cf5-8355-399519c639a6 | Product name | 1 | 20170424 |
| a993dfc5-f219-4460-bde6-30dd724d9ef0 | Product name | 1 | 20160818 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 51672-2030-3 | ML - Milliliter | 51672-2030 | 6438d50f-2bf2-4061-a793-5d3f37fb4b61 | 1 | 2012-07-24 |
| 51672-2030-5 | ML - Milliliter | 51672-2030 | 50c5526b-5725-4806-b309-7c4fdb3242e8 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Oxymetazoline Hydrochloride | ACTIVE INGREDIENT | K89MJ0S5VY | 1 | |
| Oxymetazoline | ACTIVE MOIETY | 8VLN5B44ZY | 1 | |
| benzalkonium chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 1 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| polyethylene glycol 1450 | INACTIVE INGREDIENT | OJ4Z5Z32L4 | 1 | |
| povidone | INACTIVE INGREDIENT | FZ989GH94E | 1 | |
| propylene glycol | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| sodium phosphate, dibasic, anhydrous | INACTIVE INGREDIENT | 22ADO53M6F | 1 | |
| sodium phosphate, monobasic, monohydrate | INACTIVE INGREDIENT | 593YOG76RN | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51672-2030 | 51672-2030-5, 51672-2030-3 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 3 | 2025-03-13 | full-release | 2026-06-01 00:57:11 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| povidone | POVIDONE | FZ989GH94E | IMPLANT / SUBCUTANEOUS | 6 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRAMUSCULAR | 120 mg | ||
| povidone | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| povidone | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SYRUP / ORAL | 20.6 mg/5ml | ||
| povidone | POVIDONE | FZ989GH94E | SYSTEM / TOPICAL | 41 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / TOPICAL | 0.46 %w/v | ||
| benzalkonium chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SPRAY / NASAL | 1 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 1.84 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SYRUP / ORAL | 20.6 mg/5ml | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRAMUSCULAR | 13 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRA-ARTICULAR | 14 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SOLUTION / INTRAVENOUS | 27 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 15.55 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | OINTMENT / TOPICAL | 921 mg | ||
| povidone | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 32 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | TABLET / ORAL | 31.72 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SYRUP / ORAL | 20.6 mg/5ml | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | SUPPOSITORY / URETHRAL | 9.75 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | TABLET, DELAYED RELEASE / ORAL | 35 mg | ||
| povidone | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE / ORAL | NA | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / INTRAVESICAL | 0.12 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SUSPENSION / SUBCUTANEOUS | 0.07 %w/v | ||
| povidone | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRAMUSCULAR | 13 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 15.55 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION/ DROPS / OPHTHALMIC | 8 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / SOFT TISSUE | 13 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | LOTION / TOPICAL | 8 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | CREAM / TOPICAL | 38 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRALESIONAL | 13 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | LOTION, AUGMENTED / TOPICAL | 14 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | CAPSULE, EXTENDED RELEASE / ORAL | 91 mg | ||
| povidone | POVIDONE | FZ989GH94E | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / INTRAMUSCULAR | 120 mg | ||
| povidone | POVIDONE | FZ989GH94E | SUSPENSION/ DROPS / OPHTHALMIC | 0.6 %w/v | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | CAPSULE / ORAL | 600 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | SOLUTION / TOPICAL | 0.46 %w/v | ||
| povidone | POVIDONE | FZ989GH94E | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 32 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | CAPSULE, EXTENDED RELEASE / ORAL | 91 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, SUSPENSION / INTRAVITREAL | 0.04 %w/v | ||
| povidone | POVIDONE | FZ989GH94E | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 350 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION / ORAL | 10.06 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, FOR SUSPENSION / ORAL | 2 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET / SUBLINGUAL | 6 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, DELAYED RELEASE / ORAL | 53 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | SOLUTION / ORAL | 6108 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | CAPSULE / ORAL | 600 mg | ||
| sodium phosphate, monobasic, monohydrate | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 15.55 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | TABLET / ORAL | 0.6 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, ORALLY DISINTEGRATING / ORAL | 15.03 mg | ||
| polyethylene glycol 1450 | POLYETHYLENE GLYCOL 1450 | OJ4Z5Z32L4 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| povidone | POVIDONE | FZ989GH94E | TABLET, FILM COATED / ORAL | 240 mg | ||
| povidone | POVIDONE | FZ989GH94E | CAPSULE, COATED PELLETS / ORAL | 10.03 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oxymetazoline Hydrochloride 12-Hour | OXYMETAZOLINE HYDROCHLORIDE | Sun Pharmaceutical Industries, Inc. | 34a79f8b-32b7-48db-a895-c942cc795292 | 2026-07-16 | Warnings | 51672-2030-3 51672-2030-5 51672-2030 51672203003 51672203005 56bb5577-e3d4-ae0b-e063-6394a90ab52c 34a79f8b-32b7-48db-a895-c942cc795292 |
Adverse event summaries are temporarily unavailable. Other product information remains available.